Boston Common Asset Management LLC Has $703,000 Stock Holdings in Dr. Reddy's Laboratories Limited (NYSE:RDY)

Boston Common Asset Management LLC raised its holdings in shares of Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) by 194.9% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 53,275 shares of the company's stock after buying an additional 35,210 shares during the quarter. Boston Common Asset Management LLC's holdings in Dr. Reddy's Laboratories were worth $703,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. SG Americas Securities LLC acquired a new position in shares of Dr. Reddy's Laboratories in the 4th quarter valued at $145,000. Blue Trust Inc. increased its stake in shares of Dr. Reddy's Laboratories by 46.3% in the 4th quarter. Blue Trust Inc. now owns 18,210 shares of the company's stock valued at $288,000 after buying an additional 5,763 shares during the period. Foster Group Inc. acquired a new stake in Dr. Reddy's Laboratories in the fourth quarter worth about $216,000. Hanson & Doremus Investment Management grew its position in shares of Dr. Reddy's Laboratories by 400.0% during the 4th quarter. Hanson & Doremus Investment Management now owns 23,170 shares of the company's stock worth $366,000 after buying an additional 18,536 shares during the period. Finally, Caprock Group LLC grew its holdings in Dr. Reddy's Laboratories by 280.3% during the 4th quarter. Caprock Group LLC now owns 58,563 shares of the company's stock worth $925,000 after acquiring an additional 43,165 shares during the period. 3.85% of the stock is currently owned by institutional investors and hedge funds.

Dr. Reddy's Laboratories Stock Down 0.3%

Shares of Dr. Reddy's Laboratories stock traded down $0.04 on Friday, hitting $14.71. The company had a trading volume of 1,612,844 shares, compared to its average volume of 1,484,237. The firm has a market capitalization of $12.28 billion, a P/E ratio of 23.42 and a beta of 0.33. Dr. Reddy's Laboratories Limited has a twelve month low of $12.26 and a twelve month high of $16.89. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.92 and a quick ratio of 1.38. The stock has a 50-day moving average of $13.68 and a 200-day moving average of $14.01.

Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last posted its quarterly earnings data on Friday, May 9th. The company reported $0.22 earnings per share for the quarter, topping the consensus estimate of $0.20 by $0.02. The company had revenue of $996.17 million during the quarter, compared to analysts' expectations of $83.70 billion. Dr. Reddy's Laboratories had a return on equity of 17.87% and a net margin of 17.25%. Research analysts predict that Dr. Reddy's Laboratories Limited will post 0.8 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen upgraded Dr. Reddy's Laboratories from a "hold" rating to a "buy" rating in a research report on Thursday, May 8th.

Dr. Reddy's Laboratories Company Profile

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.